Hemangiomas of Infancy: Strawberry Birthmarks and Propranolol Treatment

Understanding Infantile Hemangiomas

Infantile hemangiomas are benign vascular tumors arising from endothelial cells that present in infancy as red or purple lesions. The name "strawberry birthmark" derives from the appearance of superficial hemangiomas, which resemble red strawberries on the skin surface. Hemangiomas represent the most common vascular tumor of childhood, affecting 4-5% of infants by age 1 year. Most hemangiomas are benign and spontaneously regress during childhood, though some require treatment for functional impairment or cosmetic concerns. The advent of propranolol therapy has revolutionized hemangioma management, offering an effective systemic treatment that accelerates regression and prevents complications.

Classification and Types

Infantile hemangiomas are classified based on depth of involvement: superficial hemangiomas appear as bright red, raised lesions; deep hemangiomas appear as bluish, compressible masses beneath the skin; and mixed hemangiomas involve both superficial and deep components. Superficial lesions tend to have the classic "strawberry" appearance. Deep lesions may appear as dimples or swelling without much color change. Most hemangiomas are solitary (80%), though some infants develop multiple lesions. Location varies, with the most common sites being the face and neck (60%), trunk (25%), and extremities (15%). Rare complications of hemangiomas include ulceration, bleeding, visual obstruction, or airway compromise.

Natural History and Proliferation

A distinctive feature of infantile hemangiomas is their biphasic natural history. Most hemangiomas are not present at birth but appear during the first weeks to months of life. The proliferative phase typically lasts 3-12 months, during which rapid growth occurs, reaching maximum size. Growth then slows, and the involutional phase begins, characterized by spontaneous regression. Spontaneous regression occurs in 50% of hemangiomas by age 5 years, 90% by age 9 years, and nearly 99% eventually regress. However, the timeline is unpredictable, and complete regression may take years. Residual changes including skin redundancy, discoloration, or scarring may persist after involution.

Complications and Indications for Treatment

While most hemangiomas follow a benign course, some require treatment due to functional impairment or cosmetic concerns. Periorbital hemangiomas can cause visual obstruction, astigmatism, or amblyopia, requiring intervention. Perioral hemangiomas may impair feeding. Large facial hemangiomas create cosmetic concerns. Hepatic hemangiomas can rarely cause complications. Ulcerated hemangiomas cause pain and risk scarring. PHACES syndrome (posterior fossa brain malformations, hemangioma, arterial anomalies, cardiac defects, eye abnormalities, sternal cleft) can occur with large facial hemangiomas and requires neuroimaging and cardiac evaluation. Indications for treatment must be carefully considered against risks of therapy.

Treatment with Propranolol

Propranolol, a nonselective beta-blocker, represents first-line pharmacologic treatment for hemangiomas requiring intervention. The mechanism of action on hemangiomas is not completely understood but likely involves vasoconstriction, decreased endothelial proliferation, and promotion of apoptosis. Treatment typically results in color lightening within days to weeks and size reduction over weeks to months. Oral propranolol dosing is typically 2-3 mg/kg/day divided into 2-3 doses, with dose escalation to maximum doses of 3.5 mg/kg/day based on response and tolerance. Treatment is generally continued for 6-12 months to allow maximum benefit. Response rates showing significant improvement exceed 90% with propranolol therapy. Common side effects include sleep disturbance, diarrhea, and decreased appetite; serious side effects are rare when appropriately monitored.

Alternative and Adjunctive Therapies

Topical treatments including imiquimod cream and timolol ophthalmic solution may be used for limited superficial hemangiomas, though efficacy is variable and less consistent than systemic propranolol. Intralesional corticosteroid injection can be used for localized lesions but is less commonly employed since propranolol availability. Pulsed dye laser therapy may accelerate involution of superficial components and improve cosmetic outcomes, often used as adjunctive therapy with propranolol. Surgical excision is reserved for hemangiomas unresponsive to medical therapy or causing severe functional impairment. Combination therapies may be necessary for extensive or refractory lesions.

Frequently Asked Questions

Will the strawberry mark go away? Yes. Most hemangiomas spontaneously regress over years, though timeline is unpredictable.

Should we treat it or wait? Treatment depends on location, size, and risk of complications. Many hemangiomas warrant observation; others benefit from early treatment.

Is propranolol safe? Propranolol is safe when used appropriately with proper monitoring. Benefits for significant hemangiomas typically outweigh risks.

What about side effects? Common side effects are mild; serious effects are uncommon with appropriate monitoring and dosing.

Will treatment leave scars? Appropriate treatment can prevent scarring that might result from hemangioma ulceration or uncomplicated involution changes.

References